Related Experiment Videos

Hypoglycemia-induced myocardial infarction: an unusual adverse effect of sulfonylureas

Jen-Hung Chang, Chin-Feng Tseng, Jen-Yu Wang

    International Journal of Cardiology
    |June 22, 2006
    PubMed

    Insights

    Hypoglycemia, a common issue in diabetes patients on sulfonylureas, can lead to serious cardiovascular events like myocardial infarction. This case highlights the need to consider cardiac risks alongside neurologic concerns in sulfonylureas therapy.

    Area of Science:

    • Cardiology
    • Endocrinology
    • Pharmacology

    Background:

    • Sulfonylureas are widely prescribed oral hypoglycemic agents for type 2 diabetes management.
    • Hypoglycemia is a known adverse effect of sulfonylureas, primarily associated with neurological complications.
    • The potential for cardiovascular side effects stemming from sulfonylureas-induced hypoglycemia remains under-explored.

    Observation:

    • A 77-year-old male patient on sulfonylureas therapy presented with symptoms indicative of myocardial infarction.
    • The patient experienced severe hypoglycemia preceding the cardiac event.
    • Diagnostic workup confirmed hypoglycemia as the likely trigger for the myocardial infarction.

    Findings:

    • This case presents a rare instance of hypoglycemia-induced myocardial infarction in a patient treated with sulfonylureas.
    • The findings suggest a direct or indirect link between severe hypoglycemia and acute coronary events.
    • Sulfonylureas, through profound glucose lowering, may precipitate cardiac ischemia in susceptible individuals.

    Implications:

    • Clinicians should maintain a high index of suspicion for cardiovascular events in patients experiencing sulfonylureas-induced hypoglycemia.
    • Risk stratification for cardiac complications may be warranted in diabetic patients on sulfonylureas, especially those with a history of cardiovascular disease.
    • Further research is needed to elucidate the mechanisms underlying hypoglycemia-related myocardial infarction and to inform safer prescribing practices for sulfonylureas.

    Related Concept Videos

    Oral Hypoglycemic Agents: Sulfonylureas01:17

    Oral Hypoglycemic Agents: Sulfonylureas

    Sulfonylureas are oral hypoglycemic agents utilized in treating type 2 diabetes. They are characterized by their unique sulfonylurea chemical structure. The family of sulfonylureas is divided into generations. First-generation sulfonylureas, including tolbutamide (Orinase), chlorpropamide (Diabinese), and tolazamide (Tolinase), trigger insulin release from pancreatic β cells and enhance peripheral tissues' insulin sensitivity. The second-generation members, such as glipizide (Glucotrol),...
    Hypoglycemia01:26

    Hypoglycemia

    Hypoglycemia is a blood glucose level below 70 mg/dL. It commonly occurs in individuals using insulin or insulin-secreting drugs, but may also arise in non-diabetic conditions. People with type 1 diabetes are at the highest risk because they depend on exogenous insulin. People with type 2 diabetes are also at risk, especially when treated with insulin or medications such as sulfonylureas, which increase insulin release regardless of blood glucose levels. It develops when insulin levels exceed...
    Hypoglycemia and Glucagon01:15

    Hypoglycemia and Glucagon

    Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
    Oral Hypoglycemic Agents: Glinides01:06

    Oral Hypoglycemic Agents: Glinides

    Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
    Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

    Oral Hypoglycemic Agents: Biguanides and Glitazones

    Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
    Insulin: Dosing Regimen and Adverse Effects01:16

    Insulin: Dosing Regimen and Adverse Effects

    Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
    The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...